Pulse Biosciences, Inc. (Nasdaq: PLSE), pioneer of the novel nPulse™ platform using proprietary Nanosecond Pulsed Field Ablation (nsPFA™), today announced a new strategic alignment to prioritize and ...
Pulse Biosciences recently reported first patient treatments in a multi-center, first-in-human feasibility study of its FDA-cleared nPulse Vybrance Percutaneous Electrode System using nanosecond ...
Pulse Biosciences (Nasdaq:PLSE) today announced clinical findings demonstrating the durability of its nPulse Vybrance system.
12d
Pulse Biosciences to Present at the Oppenheimer 36th Annual Healthcare MedTech & Services Conference
Pulse Biosciences, Inc. (Nasdaq: PLSE), developer of the novel nPulse™ technology using its proprietary Nanosecond Pulsed ...
Nanosecond PFA Cardiac Surgical System for ablation of cardiac tissue to be highlighted in presentation and poster sessions. “We believe the Nanosecond PFA Cardiac Surgical System has the potential to ...
HAYWARD, Calif.--(BUSINESS WIRE)-- Pulse Biosciences, Inc. (PLSE), a company leveraging its novel nPulse™ technology using its proprietary Nanosecond Pulsed Field Ablation™ (nanosecond PFA or nsPFA™) ...
This story was originally published on MedTech Dive. To receive daily news and insights, subscribe to our free daily MedTech Dive newsletter. Pulse Biosciences said Thursday it got the Food and Drug ...
Hosted on MSN
Pulse Biosciences targets Q1 completion of PRECISE-BTN study enrollment as clinical adoption grows
CEO Paul LaViolette highlighted significant momentum across Pulse Biosciences’ three market development programs, emphasizing early adoption and progress in clinical trials. LaViolette stated, "We are ...
Pulse Biosciences (NASDAQ:PLSE) will release its quarterly earnings report on Thursday, 2026-02-19. Here's a brief overview for investors ahead of the announcement. Analysts anticipate Pulse ...
Pulse Biosciences is a novel bioelectric medicine company committed to health innovation that has the intention as well as potential to improve the quality of life for patients. The Company’s ...
Pulse Biosciences is a novel bioelectric medicine company committed to health innovation that has the intention as well as the potential to improve the quality of life for patients. The Company’s ...
Pulse Biosciences, Inc. (Nasdaq: PLSE)(the “Company” or “Pulse Biosciences”), a company leveraging its novel and proprietary Nanosecond Pulsed Field Ablation™ (nanosecond PFA or nsPFA™) technology, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results